Congrats to Ashuvinee Elangovan for winning the GRC and BGSA travel awards!
Ashuvinee Elangovan, a 2nd year graduate student in the lab won travel awards from the Gordon Research (GRC) Conferences and the Biomedical Graduate Student Association (BGSA) for the upcoming Gordon conference on IGF and Insulin System in Physiology and Disease in Ventura, CA.
Congratulations to Nilgun Tasdemir on her new publication!
Abstract. BACKGROUND: Invasive lobular carcinoma (ILC) is a histological subtype of breast cancer with distinct molecular and clinical features from the more common subtype invasive lobular carcinoma (IDC).www.biorxiv.org
We provide evidence that loss of E-cadherin hyperactivates the IGF1R pathway and increases sensitivity to IGF1R/InsR targeted therapy, thus identifying the IGF1R pathway as a potential novel target in E-cadherin–deficient breast cancers such as invasive lobular cancer.
Congratulation Dr. Nilgun Tasdemir and coauthors for their new publication generating an invaluable resource for lobular breast cancer research. Comprehensive characterization of ILC models.
Our latest paper focused on lobular breast cancer is now available. Role for SREBP1 and other regulators of fatty acid and cholesterol synthesis in invasive lobular breast cancer.
Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation.
Abstract
The study of circulating tumor cells (CTCs) offers pathways to develop new diagnostic and prognostic biomarkers that benefit cancer treatments. In order to fully exploit and interpret the information provided by CTCs, the development of a platform is reported that integrates acoustics and microfluidics to isolate rare CTCs from peripheral blood in high throughput while preserving their structural, biological, and functional integrity. Cancer cells are first isolated from leukocytes with a throughput of 7.5 mL h-1 , achieving a recovery rate of at least 86% while maintaining the cells’ ability to proliferate. High-throughput acoustic separation enables statistical analysis of isolated CTCs from prostate cancer patients to be performed to determine their size distribution and phenotypic heterogeneity for a range of biomarkers, including the visualization of CTCs with a loss of expression for the prostate specific membrane antigen. The method also enables the isolation of even rarer, but clinically important, CTC clusters.